IP Library Granted Patent US 10,130,698
Granted Patent B2
US 10,130,698 · App. 15/038,765 · Granted Nov 20, 2018

Vaccine against porcine circo virus type 2

Inventors: Vicky Fachinger (Bad Soden, DE); Melanie Sno (Venlo, NL); Maarten Hendrik Witvliet (Oostrum, NL)
Assignee: Intervet Inc.
A61K39/12A61K39/0241A61K39/105C12N7/00A61K2039/54A61K2039/552A61K2039/55566A61K2039/70C12N2750/10034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,130,698
App. No.
15/038,765
Granted
Nov 20, 2018
Kind
B2
Abstract

The present invention pertains to a vaccine comprising a non-replicating immunogen of porcine circo virus type 2 for use in prophylactically treating an animal that has circulating antibodies directed against porcine circo virus type 2, against an infection with pathogenic porcine circo virus type 2 by a single dose administration of the vaccine into the dermis of the animal.

Claims (6)

1. A method of prophylactically treating an animal against an infection with pathogenic porcine circo virus type 2 comprising administering a single dose of a vaccine comprising recombinantly expressed ORF2 protein of porcine circo virus type 2 and a Lawsonia intracellularis antigen into the dermis of an animal that has circulating antibodies directed against porcine circo virus type 2; wherein the vaccine is administered with a needle-less vaccination device.

2. The method of claim 1 , wherein the single dose administration comprises less than 0.5 ml of the vaccine.

3. The method of claim 2 , wherein the single dose administration comprises less than 0.2 ml of the vaccine.

4. The method of claim 1 , wherein the vaccine comprises an adjuvant comprising mineral oil, wherein the amount of mineral oil in the vaccine is between 1 and 10% v/v.

5. The method of claim 3 , wherein the vaccine comprises an adjuvant comprising mineral oil, wherein the amount of mineral oil in the vaccine is between 1 and 10% v/v.

6. The method of claim 5 , wherein the amount of mineral oil is between 2.5 and 5% v/v.

Assignments (2)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2016
From: FACHINGER, VICKY; SNO, MELANIE; WITVLIET, MAARTEN HENDRIK
To: INTERVET INC.
Reel/Frame 038729/0918 →
Priority Claims (1)
EP 13195515 · Dec 3, 2013 · regional
Continuity (1)
Related Publication 20170157236A1 · Jun 8, 2017